Oncoinvent ASA updates key details for NOK 130m rights issue

Oncoinvent ASA, in conjunction with BerGenBio ASA, has released updated key information regarding its fully underwritten rights issue, aiming to raise NOK 130 million. Key dates include a "last day including rights" of November 11, 2025, an ex-date of November 12, 2025, and a record date of November 13, 2025.

The subscription price will be determined after the merger's completion, specifically on the ninth trading date, aligning with the theoretical share price exclusive of subscription rights and discounted by approximately 35% from the volume-weighted average price over the three trading days leading up to and including the pricing date.

The subscription ratio is set at 1:1 for new shares in the combined company per subscription right. The rights will be listed on Euronext Oslo Børs. The rights issue is contingent on the merger's completion and the publication of a prospectus, expected around October 28, 2025.